EGFR: A molecular lab rat let loose in systems biology

December 17, 2003

SAN FRANCISCO -- Epidermal growth factor and its receptor system, or EGFR, is well-trodden territory in molecular biology. And it's no wonder. This is one critical community of proteins, responsible for everything from the development of insect eyes and the mouse brain to human heart and skin. When EGFR breaks down, cancer and other diseases crop up.

EGFR is the veritable lab rat of molecular systems. Going on five decades now, biologists in labs around the world, not unlike motorheads under the hood with carburetors and plugs, have plucked out and examined every conceivable component of the EGFR network.

Along comes systems biology, shiny-new and bursting with promise, outfitted with high-powered computing and modeling capabilities that are being brought to bear on the fundamental problems of human physiology and disease pathology. And what undiscovered country does H. Steven Wiley and his colleagues at the Pacific Northwest National Laboratory choose to flood with the piercing light of this new science?

Why, naturally, this same receptor network.

"A lot of people ask, 'Why this system? It's the prototypical receptor system. We know everything about it. We know all the parts,' " says Wiley, chief scientist and director of the Biomolecular Systems Initiative at the Department of Energy lab in Richland, Wash.

Wiley's reply: The whole is much more than the sum of its parts -- receptors, ligands, enzymes, substrates -- and a great starting point if you know what each of those parts is.

"We're looking at the whole family of parts that govern cell behavior," Wiley says. "We need to know how they react with each other and other parts of the system."

Wiley likens the known world of the EGFR to a big-city phone book. It's all there, in black and white and yellow, and it tells you next to nothing about the city or how its inhabitants interact.

"The systems approach," Wiley says, "enables us to make counterintuitive predictions, and then test them." Systems biologists must check their assumptions at the lab door. It was once dogma in drug development, for example, that the molecules of choice were those with high binding affinity to their receptors, the proverbial locksets on the cell membranes. Clicking the deadbolt either blocks or unlocks the desired reaction in the cell. It turns out that a strong and decisive snap of the bolts -- the high-affinity binding -- works for a while, but keeping the arrangement in place can drain the system.

"In one case, we were able to predict that a growth factor with a lower affinity will bind longer" -- not unlike a long-distance runner pacing for a marathon as opposed to, say, the 60-meter-dash of the high-affinity molecule.

The systems approach, he says, also forces "us to be better molecular biologists." In order to test a model that calls for a mathematically precise solution, Wiley and his colleagues have to cajole molecules into performing unnatural acts. In one experiment, to test their assumptions about what EGFR molecules called ligands actually do, they had to re-engineer a cell, move the ligands in time and space, "swap out ligand parts."

"There are five ligands for the EGF receptor," Wiley says. "We wondered why five? Few people cared about the number of ligands. They figured domain 1 in the first ligand does the same thing in the second ligand, so what's the difference?"

Big, it turns out. If you swap domains, you alter the rates of secretions on the surface of the cell, and the cells can't organize into tissues. "We can make cells come together and come apart by swapping domains."

By defining the functional domains, Wiley listened in on a previously unheard conversation inside the cell. And he didn't care so much about why they were talking as what they were saying. "We just wanted to know what information that functional domain has on it."

Knowing how and what information is being passed inside a cell is the key in "network biology," Wiley says. "To kill a cancer, you have to attack a network. The cancer is set up to survive. A part of a normal cell might ask, 'am I in the right place, at the right time?' If the answer is no, the cell commits suicide."

Cancer cells are adept at either shutting out the signal or convincing themselves they are in the right place. "How do we hammer the proper signal through to a cancer cell? What parts of the network say 'live,' and what parts say 'die.' We have to find a way to make that decision process come out the way we want it to go. We have to talk to the cancer, persuade it to die. Then the patient can live."
NOTE: Pacific Northwest National Laboratory's H. Steven Wiley's will talk on "The EGF Receptor Network" at the American Society for Cell Biology annual meeting in San Francisco, on Wed., Dec. 17, 10:30 a.m. - noon. Wiley's talk will be part of a symposium he has organized on "Biomolecular Networks in Cell Biology"

DOE/Pacific Northwest National Laboratory

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to